
News|Articles|January 1, 2012
FDA Pipeline Preview, January 2012 (Alexza Pharmaceuticals, Pfizer, Celladon, Vertex, Avedro)
Recent FDA action (through December 2011) related to staccato loxapine, axitinib, mydicar, kalydeco, riboflavin ophthalmic solution, minocycline hydrochloride
Advertisement
Recommendations for approval
Fast-track designation
Priority review
• First-time generic approval
MInocycline hydrocholride extended-release tablets in 45-mg, 55-mg, 90-mg, and 135-mg strengths (equiv to Solodyn)
LUPIN PHARMACEUTICALS
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
4
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
5


























